Leukemia, Myelodysplastic Syndromes
Conditions
Keywords
leukemia, myelodysplastic, myeloid, lymphoblastic, diet, infection, hematopoietic, stem cell, transplant
Brief summary
This is an open-label, two-arm, phase III non-inferiority trial to evaluate the safety of a liberalized hospital diet inclusive of fresh fruits and vegetables to a neutropenic diet in patients with prolonged neutropenia. Both cohorts and diets will adhere to the hygiene and common sense advice listed in the FDA-endorsed food safety guidelines.
Interventions
OTHERDiet
Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
Sponsors
University of Florida
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older * Undergoing treatment for hematologic malignancies or HSCT as outlined below: * Underlying diagnosis for non-HSCT patients: * Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving induction or reinduction chemotherapy; OR * Acute lymphoblastic leukemia (ALL) receiving an intensive induction chemotherapy (e.g., HyperCVAD±R, CALGB9251, Larsons protocol) with an expected duration of neutropenia of ≥7 days; OR * Allogeneic or autologous HSCT for any indication. For patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is ≥ 7 days are permitted and the patient must reside in the hospital * Expected duration of neutropenia of ≥ 7 days
Exclusion criteria
* Use of anti infectives for treatment of active systemic infections within 7 days prior to initiation of study diet * Untreated major infection at presentation * Patients with uncontrolled invasive fungal infection (defined as those who have not completed at least 6 weeks of treatment; or who are symptomatic with two CT scans, at least 1 week apart showing uncontrolled disease at the time of initiation of study diet) * Uncontrolled HIV, Hepatitis B and C infection * Receipt of nutrition via enteral tube or total parenteral nutrition at the time of enrollment * Patients unwilling to eat fresh fruit and/or vegetables * Planned management of neutropenia in the outpatient setting
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of major infections | 1 year | The primary objective of the trial is to compare the incidence of major infections in subjects undergoing HSCT or receiving induction chemotherapy for acute leukemia with prolonged neutropenia (less than or equal to 7 days) who are receiving either Diet A or Diet B. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Admission frequency | 1 year | This secondary objective of the trial will examine the admission frequency to the intensive care unit (ICU). |
| Compliance | 1 year | This secondary objective of the trial will evaluate the degree of compliance to each diet from the time of initiation of the diet intervention until either the Absolute Neutrophil Count (ANC) is equal to or less than 500/mm3, the subject is discharged from the hospital, the subject is transferred from the unit, or after 30 days of ANC less than 500/mm3. |
| Patient-Generated Subjective Global Assessment (PG-SGA) | 1 year | This secondary objective of the trial will evaluate the impact of each diet on nutritional status as assessed by PG-SGA. |
| Incidence of mucositis | 1 year | This secondary objective of the trial will evaluate the impact of mucositis on dietary intake. |
| Incidence of infections in each diet group | 1 year | This secondary objective of the trial is to compare the impact of diet on severe infections including: septic shock, bloodstream infection, invasive fungal infection, upper respiratory infection, infectious & non-infectious pneumonia, C. difficile infection, Vancomycin-resistant & -sensitive enterococcal colonization, Vancomycin-resistant & -sensitive enterococcal infections, febrile neutropenia, typhlitis, lower tract respiratory viral infections, infection-related mortality, and admission to the ICU. |
| Quality of life (QoL) | 1 year | This secondary objective of the trial is to compare the QoL between diets as assessed by FACT-G. |
| Overall survival (OS) | 1 year | This secondary objective of the trial is to evaluate OS from 1 year following randomization |
| Progression free survival (PFS) | 1 year | This secondary objective of the trial is to evaluate PFS from 1 year following randomization |
| Incidence of graft vs.host disease (GVHD) | 1 year | This secondary objective of the trial is to evaluate the incidence of GVHD in allogeneic HSCT subjects only. |
| Symptom incidence | 1 year | This secondary objective of the trial is to compare symptoms between diets using the MDASI tool. |
Countries
United States
Outcome results
None listed